Local Institution

Meldola Fc 47014

0 studies enrolling now · 13 studies all time

What they study most

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Endometrial Cancer, Liver Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer (MCRC), Multiple Myeloma, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Small Cell Lung Carcinoma

Studies at this site

• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) — Completed
• Phase I Combination Ixabepilone + Cisplatin — Completed
• Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone — Completed
• Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma — Completed
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer — Stopped early
• Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies — Completed
• A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer — Completed
• Phase I/II Combination With Irinotecan- Erbitux — Completed
• Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer — Stopped early